Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a
medical technology company focused on developing and
commercializing non-invasive wearable diagnostic devices and
supporting personalized lifestyle coaching programs, today
announces financial results for the second quarter ended September
30, 2020 and provides a corporate update.
Recent and Second Quarter Highlights include:
- In-licensed global rights to Healthimation, LLC’s mobile
application based digital program, a well-validated and
award-winning 12-week program to help patients manage their weight
as part of a diabetes prevention or management program. The program
is intended to be combined with the Company’s proBEAT™ non-invasive
Glucose monitoring patch, with the aim of empowering users with
knowledge of factors that could affect their blood glucose
levels.
- Appointed Justin McLarney as the Company’s Chief Financial
Officer
- Commissioned the integration of data from third-party wearable
devices into the proBEAT™ app.
- Submitted the PMA application for sugarBEAT® to the United
States Food and Drug Administration (FDA)
- Completed $11.5M public offering ($10.7M after associated
costs)
- Terminated ATM with Maxim
“The second quarter has been pivotal to our Company, as we have
laid the groundwork for product launch of sugarBEAT® in the UK and
Europe, and a diabetes management and reversal program in the USA,”
commented Faz Chowdhury, Nemaura’s CEO. “We continue to
carefully manage our finances as we plan for a multinational launch
and believe that we are at the forefront of changing the way
consumers approach managing and preventing diabetes.”
In December 2020 in the U.S., Nemaura plans to launch proBEAT™,
a non-invasive, wearable glucose monitor that will gather data on
factors affecting blood glucose profiles, combined with a
behavioral change and weight management digital app that was
developed by Healthimation Inc. that may help diabetic and
pre-diabetic patients better manage, reverse, or prevent the onset
of diabetes. In the U.S., there are currently 88 million
patients considered to be pre-diabetic and 25 million patients with
Type 2 diabetes. Worldwide, there are 420 million patients
with diabetes and over 1 billion people considered
pre-diabetic.
Second Quarter 2020 Financial Results
Net loss for the second quarter of 2020 was $1,581,217 as
compared to $1,117,040 during the same period of 2019.
Research and development expenses were $456,280 and $462,517 for
the three-month periods ended September 30, 2020 and 2019,
respectively. This continues to be largely composed of
expenditure on wages and sub-contractor activities incurred in
finalizing the product design for the sugarBEATTM device in order
to enable scaling of production capacity.
General and administrative expenses were $771,533 and $654,523
for the three-month periods ended September 30, 2020 and 2019,
respectively. Given the nature of the Company’s activities
has remained unchanged, the cost drivers in this area have also
remained consistent and are largely representative of fees for
legal, professional, consultancy, audit services, investor
relations, insurance, and wages.
The Company also incurred a charge of $353,404 for the
three-month period ended September 30, 2020 on account of the
accretion of debt discount in relation to the Secured Loan Note
that the Company entered into in April 2020.
Cash as of September 30, 2020 was $16,948,939. About
Nemaura Medical, Inc.
Nemaura Medical Inc. is a medical technology company developing
and commercializing non-invasive wearable diagnostic devices.
The company is currently commercializing sugarBEAT® and
proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical
device, is a non-invasive and flexible continuous glucose monitor
(CGM) providing actionable insights derived from real time glucose
measurements and daily glucose trend data, which may help people
with diabetes and pre-diabetes to better manage, reverse, and
prevent the onset of diabetes. Nemaura has submitted a PMA
(Premarket Approval Application) for sugarBEAT® to the U.S. FDA.
proBEAT™ combines non-invasive glucose data processed using
artificial intelligence and a digital healthcare subscription
service and is expected to be launched in the U.S. as a general
wellness product.
The Company sits at the intersection of the global Type 2
diabetes market that is expected to reach nearly $59 billion by
2025, the $50+ billion pre-diabetic market, and the wearable
health-tech sector for weight loss and wellness applications that
is estimated to reach $60 billion by 2023.
For more information, please visit www.NemauraMedical.com.
Cautionary Statement Regarding Forward-Looking
Statements:
The statements in this press release that are not historical
facts may constitute forward-looking statements that are based on
current expectations and are subject to risks and uncertainties
that could cause actual future results to differ materially from
those expressed or implied by such statements. Those risks
and uncertainties include, but are not limited to, the launch of
proBEAT™ in the US, risks related to regulatory status and the
failure of future development and preliminary marketing efforts,
Nemaura’s ability to secure additional commercial partnering
arrangements, risks and uncertainties relating to Nemaura and its
partners’ ability to develop, market and sell proBEAT™, the
availability of substantial additional equity or debt capital to
support its research, development and product commercialization
activities, and the success of its research, development,
regulatory approval, marketing and distribution plans and
strategies, including those plans and strategies related to both
proBEAT™ digital health, and sugarBEAT®. There can be no
assurance that the company will be able to reach a part of or any
of the global market for CGM with its products/services. The FDA
reserves the right to re-evaluate their decision that proBEAT™
qualifies as a general wellness product should it become aware of
any issues such as skin irritation or other adverse events from the
device, as well as any misuse impacting patient safety, and any
other reason as the FDA may see fit at its discretion to determine
the product does not fit the definition of a general wellness
product. These and other risks and uncertainties are
identified and described in more detail in Nemaura’s filings with
the United States Securities and Exchange Commission, including,
without limitation, its Annual Report on Form 10-K for the most
recently completed fiscal year, its Quarterly Reports on Form 10-Q,
and its Current Reports on Form 8-K. Nemaura undertakes no
obligation to publicly update or revise any forward-looking
statements.
Contact:
Jules Abraham CORE IR 917-885-7378 julesa@coreir.com
NEMAURA MEDICAL INC.Condensed
Consolidated Balance Sheets
|
As of September
30,2020($) |
As of March 31, 2020($) |
|
(Unaudited) |
|
ASSETS |
|
|
Current assets: |
|
|
Cash |
16,948,939 |
|
106,107 |
|
Prepaid expenses and other receivables |
358,404 |
|
452,463 |
|
Inventory (raw materials) |
411,620 |
|
286,309 |
|
Total current assets |
17,718,963 |
|
844,879 |
|
|
|
|
Other assets: |
|
|
Property and equipment, net of accumulated depreciation |
152,893 |
|
162,064 |
|
Intangible assets, net of accumulated amortization |
237,150 |
|
213,080 |
|
Total other assets |
390,043 |
|
375,144 |
|
Total assets |
18,109,006 |
|
1,220,023 |
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
(DEFICIT) |
|
|
Current liabilities: |
|
|
Accounts payable |
155,609 |
|
293,608 |
|
Liability due to related parties |
153,533 |
|
830,093 |
|
Other liabilities and accrued expenses |
47,609 |
|
168,966 |
|
Notes payable, net of unamortized discount |
2,431,913 |
|
- |
|
Deferred revenue |
96,930 |
|
93,022 |
|
Total current liabilities |
2,885,594 |
|
1,385,689 |
|
|
|
|
Non-current portion of notes payable, net of unamortized
discount |
2,785,515 |
|
- |
|
Non-current portion of deferred revenue |
1,195,470 |
|
1,147,278 |
|
Total non-current liabilities |
3,980,985 |
|
1,147,278 |
|
Total liabilities |
6,866,579 |
|
2,532,967 |
|
|
|
|
Commitments and contingencies: |
|
|
|
|
|
Stockholders’ equity (deficit): |
|
|
Series A convertible preferred stock, $0.001 par value, 200,000
shares authorized; 0 shares issued and outstanding at September 30,
2020 and March 31, 2020 |
- |
|
- |
|
Common stock, $0.001 par value, |
|
|
42,000,000 shares authorized and 22,893,705 and 20,850,848 |
|
|
shares issued and outstanding at September 30, 2020 and March 31,
2020, respectively |
22,894 |
|
20,851 |
|
Additional paid-in capital |
31,838,383 |
|
16,589,272 |
|
Accumulated deficit |
(20,267,348 |
) |
(17,586,075 |
) |
Accumulated other comprehensive loss |
(351,502 |
) |
(336,992 |
) |
Total stockholders’ equity/ (deficit) |
11,242,427 |
|
(1,312,944 |
) |
Total liabilities and stockholders’ equity |
18,109,006 |
|
1,220,023 |
|
See notes to the unaudited condensed consolidated
financial statements.
NEMAURA MEDICAL INC.Condensed
Consolidated Statements of Comprehensive
Loss(Unaudited)
|
Three Months Ended September 30, |
Six Months Ended September 30, |
|
2020($) |
2019($) |
2020($) |
2019($) |
|
|
|
|
|
Revenue: |
- |
|
- |
|
- |
|
- |
|
Total revenue |
- |
|
- |
|
- |
|
- |
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
Research and development |
456,280 |
|
462,517 |
|
771,592 |
|
1,018,699 |
|
General and administrative |
771,533 |
|
654,523 |
|
1,367,253 |
|
1,353,532 |
|
Total operating expenses |
1,227,813 |
|
1,117,040 |
|
2,138,845 |
|
2,372,231 |
|
|
|
|
|
|
Loss from operations |
(1,227,813 |
) |
(1,117,040 |
) |
(2,138,845 |
) |
(2,372,231 |
) |
|
|
|
|
|
Interest (expense) income |
(353,404 |
) |
- |
|
(542,428 |
) |
3,926 |
|
Net loss |
(1,581,217 |
) |
(1,117,040 |
) |
(2,681,273 |
) |
(2,368,305 |
) |
|
|
|
|
|
Other comprehensive loss: |
|
|
|
|
Foreign currency translation
adjustment |
(19,334 |
) |
(7,401 |
) |
(14,510 |
) |
(23,152 |
) |
Comprehensive loss |
(1,600,551 |
) |
(1,124,441 |
) |
(2,695,784 |
) |
(2,391,457 |
) |
|
|
|
|
|
Loss per share: |
|
|
|
|
Basic and diluted |
(0.07 |
) |
(0.05 |
) |
(0.12 |
) |
(0.11 |
) |
Weighted average number of
shares outstanding |
22,384,986 |
|
20,802,197 |
|
21,636,330 |
|
20,792,967 |
|
See notes to the unaudited condensed consolidated
financial statements.
NEMAURA MEDICAL
INC.Condensed Consolidated Statements of Changes
in Stockholders’ EquityThree Months Ended
September 30, 2020 and 2019 (Unaudited)
|
Common Stock |
|
|
|
|
|
|
|
|
|
Shares |
|
Amount |
|
Additional Paid-in Capital |
|
Accumulated Deficit |
|
Accumulated Other Comprehensive Loss |
|
Total Stockholders’ Equity |
|
|
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
Balance at June 30, 2020 |
21,282,133 |
|
21,282 |
|
20,957,486 |
|
(18,686,131 |
) |
|
(332,169 |
) |
|
1,960,468 |
|
Issuance of common shares under ATM financing, net of
offering costs of $845,030 |
1,611,572 |
|
1,612 |
|
10,880,897 |
|
- |
|
|
- |
|
|
10,882,509 |
|
Foreign currency translation adjustment |
- |
|
- |
|
- |
|
- |
|
|
(19,334 |
) |
|
(19,334 |
) |
Net loss |
- |
|
- |
|
- |
|
(1,581,217 |
) |
|
- |
|
|
(1.581,217 |
) |
Balance at September 30, 2020 |
22,893,705 |
|
22,894 |
|
31,838,383 |
|
(20,267,348 |
) |
|
(351,502 |
) |
|
11,242,427 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at June 30, 2019 |
20,801,680 |
|
20,802 |
|
16,320,359 |
|
(14,677,144 |
) |
|
(355,639 |
) |
|
1,308,378 |
|
Restricted shares issued as stock-based compensation to
consultants and investor relations |
1,250 |
|
1 |
|
12,375 |
|
- |
|
|
- |
|
|
12,376 |
|
Foreign currency translation adjustment |
- |
|
- |
|
- |
|
- |
|
|
(7,401 |
) |
|
(7,401 |
) |
Net loss |
- |
|
- |
|
- |
|
(1,117,040 |
) |
|
- |
|
|
(1,117,040 |
) |
Balance at September 30, 2019 |
20,802,930 |
|
20,803 |
|
16,332,734 |
|
(15,794,184 |
) |
|
(363,040 |
) |
|
196,313 |
|
See notes to the unaudited condensed consolidated
financial statements.
NEMAURA MEDICAL
INC.Condensed Consolidated Statements of Changes
in Stockholders’ EquitySix Months Ended September
30, 2020 and 2019 (Unaudited)
|
Common Stock |
|
|
|
|
|
|
|
|
|
Shares |
|
Amount |
|
Additional Paid-in Capital |
|
Accumulated Deficit |
|
Accumulated Other Comprehensive Loss |
|
Total Stockholders’ Equity |
|
|
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
Balance at March 31 2020 |
20,850,848 |
|
20,851 |
|
16,589,272 |
|
(17,586,075 |
) |
|
(336,992 |
) |
|
(1,312,944 |
) |
Issuance of common shares under ATM financing, net of
offering costs of $967,943 |
2,004,924 |
|
2,005 |
|
14,854,674 |
|
- |
|
|
- |
|
|
14,856,679 |
|
Exercise of warrants |
37,933 |
|
38 |
|
394,437 |
|
- |
|
|
- |
|
|
394,475 |
|
Foreign currency translation adjustment |
- |
|
- |
|
- |
|
- |
|
|
(14,510 |
) |
|
(14,510 |
) |
Net loss |
- |
|
- |
|
- |
|
(2,681,273 |
) |
|
- |
|
|
(2,681,273 |
) |
Balance at September 30, 2020 |
22,893,705 |
|
22,894 |
|
31,838,383 |
|
(20,267,348 |
) |
|
(351,502 |
) |
|
11,242,427 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at March 31, 2019 |
20,765,592 |
|
20,766 |
|
15,971,905 |
|
(13,425,879 |
) |
|
(339,888 |
) |
|
2,226,904 |
|
Exercise of warrants |
2,500 |
|
2 |
|
25,998 |
|
- |
|
|
- |
|
|
26,000 |
|
Issuance of common shares under ATM financing, net of
offering costs of $9,575 |
14,338 |
|
14 |
|
142,903 |
|
- |
|
|
- |
|
|
142,917 |
|
Restricted shares issued as stock- based compensation to
consultants and investor relations |
20,500 |
|
21 |
|
191,928 |
|
- |
|
|
- |
|
|
191,949 |
|
Foreign currency translation adjustment |
- |
|
- |
|
- |
|
- |
|
|
(23,152 |
) |
|
(23,152 |
) |
Net loss |
- |
|
- |
|
- |
|
(2,368,305 |
) |
|
- |
|
|
(2,368,305 |
) |
Balance at September 30, 2019 |
20,802,930 |
|
20,803 |
|
16,332,734 |
|
(15,794,184 |
) |
|
(363,040 |
) |
|
196,313 |
|
See notes to the unaudited condensed consolidated
financial statements.
NEMAURA MEDICAL INC.Condensed
Consolidated Statements of Cash Flows(Unaudited)
|
Six Months Ended September 30, |
|
2020($) |
2019($) |
|
|
|
Cash Flows From Operating Activities: |
|
|
Net loss |
(2,681,273 |
) |
(2,368,305 |
) |
|
|
|
Adjustments to reconcile net loss to net cash used in
operating activities: |
|
|
Depreciation and amortization |
40,746 |
|
28,338 |
|
Accretion of debt discount |
542,428 |
|
- |
|
Stock-based compensation |
59,000 |
|
277,664 |
|
Changes in assets and liabilities: |
|
|
Prepaid expenses and other receivables |
94,059 |
|
263,022 |
|
Inventory |
(125,311 |
) |
(170,371 |
) |
Accounts payable |
(137,999 |
) |
59,010 |
|
Liability due to related parties |
(676,560 |
) |
100,533 |
|
Other liabilities and accrued expenses |
(121,357 |
) |
(52,608 |
) |
Net cash used in operating activities |
(3,006,267 |
) |
(1,862,717 |
) |
|
|
|
Cash Flows from Investing Activities: |
|
|
Capitalized patent costs |
(27,600 |
) |
(28,310 |
) |
Purchase of property and equipment |
(14,032 |
) |
(133,716 |
) |
Net cash used in investing activities |
(41,632 |
) |
(162,026 |
) |
|
|
|
Cash Flows from Financing Activities: |
|
|
Costs incurred in relation to ATM equity financing |
(957,193 |
) |
(9,575 |
) |
Commission paid on note payable |
(325,000 |
) |
- |
|
Proceeds from issuance of notes |
5,000,000 |
|
- |
|
Proceeds from issuance of common stock in relation to ATM
financing |
15,750,672 |
|
152,492 |
|
Proceeds from warrant exercise |
394,475 |
|
26,000 |
|
Repayments of note payable |
(82,555 |
) |
- |
|
Net cash provided by financing activities |
19,780,399 |
|
168,917 |
|
|
|
|
Net increase (decrease) in cash |
16,732,500 |
|
(1,855,826 |
) |
Effect of exchange rate changes on cash |
110,332 |
|
(113,723 |
) |
Cash at beginning of period |
106,107 |
|
3,740,664 |
|
Cash at end of period |
16,948,939 |
|
1,771,115 |
|
|
|
|
Supplemental disclosure of non-cash financing
activities: |
|
|
Prepayment of equity compensation |
- |
|
85,715 |
|
See notes to the unaudited condensed consolidated
financial statements.
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Sep 2023 to Sep 2024